sithara-geneexpressionsignature-2017.pdf (618.89 kB)
Download file

Gene expression signature: a powerful approach for drug discovery in diabetes

Download (618.89 kB)
journal contribution
posted on 01.02.2017, 00:00 authored by Smithamol Sithara, Tamsyn CrowleyTamsyn Crowley, Ken WalderKen Walder, Kathryn Aston-MourneyKathryn Aston-Mourney
Type 2 diabetes (T2D) is increasing in prevalence at an alarming rate around the world. Much effort has gone into the discovery and design of antidiabetic drugs; however, those already available are unable to combat the underlying causes of the disease and instead only moderate the symptoms. The reason for this is that T2D is a complex disease, and attempts to target one biological pathway are insufficient to combat the full extent of the disease. Additionally, the underlying pathophysiology of this disease is yet to be fully elucidated making it difficult to design drugs that target the mechanisms involved. Therefore, the approach of designing new drugs aimed at a specific molecular target is not optimal and a more expansive, unbiased approach is required. In this review, we will look at the current state of diabetes treatments and how these target the disease symptoms but are unable to combat the underlying causes. We will also review how the technique of gene expression signatures (GESs) has been used successfully for other complex diseases and how this may be applied as a powerful tool for the discovery of new drugs for T2D.

History

Journal

Journal of endocrinology

Volume

232

Issue

2

Pagination

R131 - R139

Publisher

BioScientifica

Location

Bristol, Eng.

eISSN

1479-6805

Language

eng

Publication classification

C Journal article; C1 Refereed article in a scholarly journal

Copyright notice

2017, Society for Endocrinology